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Abstract Sacral neuromodulation has been developed to
treat chronic lower urinary tract symptoms, resistant to
classical conservative therapy. The suspected mechanisms of
action include afferent stimulation of the central nervous
system and modulation of activity at the level of the brain.
Typical neuromodulation is indicated both in overactivity and
in underactivity of the lower urinary tract. In the majority of
patients, a unilateral electrode in a sacral foramen and
connected to a pulse generator is sufficient to achieve
significant clinical results also on long term. In recent years,
other urological indications have been explored.
Keywords Lower urinary tract symptoms (LUTS).Sacral
neuromodulation.Bladder pacemaker
Introduction
Chronic types of lower urinary tract dysfunction, including
urge incontinence, urgency–frequency (both included in the
overactive bladder syndrome or OAB together eventually
with nocturia) and non-obstructive urinary retention, still
present a therapeutic challenge. Most patients are initially
treated with conservative therapies including bladder
retraining, pelvic floor exercises, and biofeedback. In the
majority of patients, this standard regimen is supported with
pharmacological therapy (anticholinergics). However,
approximately 40% either do not achieve an acceptable
level of therapeutic benefit or remain completely refractory
to treatment. Alternative surgical procedures such as
bladder transsection, transvesical phenol injection of the
pelvic plexus, augmentation cystoplasty, and even urinary
diversion have been advocated for these chronic conditions.
However, these procedures have variable efficacy and have
been associated with significant morbidity and risk. There-
fore,researchintotheuseofelectricalcurrentforthetreatment
of lower urinary tract dysfunction has been initiated.
In 1878, Saxtorph reported intravesical electrostimula-
tion in patients with a contractile bladder and complete
urinary retention [1]. He inserted a special catheter with a
metal electrode transurethrally. After him, Katona, Ascoli,
and Federici applied electrostimulation in patients with
chronic neurogenic retention and hyperreflexia [2, 3]. In the
field of urology, electric currents were and are used
particularly in the bladder, the pelvic floor muscles, and
the sacral roots [4–6]. A publication by Nashold et al. in
1971 reported on a successful implantation of a neural
prosthesis in the sacral segment of the spinal cord [7]. The
implant was used to activate voiding in a patient with spinal
cord injury. Jonas and Tanagho tried to improve this
prosthesis because during stimulation not only the bladder
contracted but the urinary sphincter as well [8, 9]. Later
Tanagho and Schmidt demonstrated that the stimulation of
sacral root S3 generally modulates detrusor and sphincter
action and could be used in clinical practice [10–13]. After
two decades of experimentation with sacral root stimula-
tion, finally in October of 1997, sacral neuromodulation for
treatment of refractory urge incontinence was approved by
the Food and Drug Administration in the United States.
More than 25,000 patients underwent sacral nerve stimula-
tion (SNS) since the FDA approval.
Mechanism of action
The stimulation of afferent nerve fibers by electrical current
modulates reflex pathways involved in the filling and
P. E. V. Van Kerrebroeck (*)
Department of Urology, University Hospital Maastricht,
P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
e-mail: pvk@suro.azm.nl
Int Urogynecol J (2010) 21 (Suppl 2):S467–S474
DOI 10.1007/s00192-010-1276-0evacuation phase of the micturition cycle through spinal
circuits mediating somato–visceral interactions within the
sacral spinal cord. SNS is proposed to activate or “reset”
the somatic afferent inputs that play a pivotal role in the
modulation of sensory processing and micturition reflex
pathways in the spinal cord [14, 15]. Because beneficial
effects can be demonstrated at intensities of stimulation that
do not activate movements of striated muscle, the afferent
system is the most likely effected [16].
Urinary retention and dysfunctional voiding can be
resolved by inhibition of the guarding reflexes. Detrusor
overactivity can be suppressed by one or more pathways, i.e.,
direct inhibition of bladder preganglionic neurons, as well as
inhibition of interneuronal transmission in the afferent limb of
the micturition reflex [15].
Recent research with PET scanning indicates that at
the level of the brain, the activity of centers in the
paraventricular grey involved in activation or inhibition
of the micturition reflex, can be enhanced or reduced by
sacral nerve stimulation and results in up- or downgrading
of lower urinary tract activity [17–19]. Blok et al. reported
on the acute and chronic effects of SNS for urge
incontinence on the brain. They registered differences
between newly and chronically implanted patients in brain
areas involved in sensory and motor learning. No differ-
ences were seen in regional cerebral blood flow (rCBF) in
areas that are part of the micturition reflex. Changes in
rCBF were seen in specific areas: areas known to be
involved in micturition and areas involved in awareness
and awakeness. Acute SNS modulates sensorimotor
learning areas and these become less active during chronic
SNS [20].
Selecting patients for SNS
All patients who have symptoms of voiding dysfunction
and who cannot be helped by other measures should be
considered for SNS. Patient selection begins with a careful
history, physical examination, routine urine tests, and, very
important, the voiding diaries. Voiding diaries are a
valuable instrument during the selection and have to be
filled in carefully. Urodynamics are used to identify the
patients with detrusor overactivity with or without urinary
leakage or urinary retention. Koldewijn et al. studied
predictors of success in 100 test stimulation patients and
did not find any [21]. Scheepens et al. studied the data from
211 patients who underwent a trial stimulation (percutaneous
nerve evaluation [PNE]) to determine the clinical parameters
that can enhance the prediction of PNE success. They found
that intervertebral disk prolapse, duration of complaints,
neurogenic bladder dysfunction, and urge incontinence were
found to be significant predictive factors. However, a PNE
remains necessary to evaluate a patient’s chance of permanent
implant success objectively [22].
Cohen et al. recently published a study on motor versus
sensory response. They concluded that a good motor
response during implantation was a predictive factor (in
95% of successfully treated patients) for success while a
sensory response was not. All these patients were implanted
under local anesthesia but with intravenous sedation and
therefore the sensory perception of these patients may be
unreliable [23].
Although not clearly reported before, it is known that a
substantial part of the patients selected for SNS therapy
have a history of psychological dysfunction and/or sexual
abuse in the past. Weil et al. reported that special attention
is needed for this group of patients [24]. They noted that
patients with a history of psychological disorders, who had
a good response during temporary test stimulation, had a far
greater chance of lack of maintaining effect after permanent
implantation. Of these patients, 82% showed a poor result
after definitive implantation compared to 28% of the
patients without a history of psychological disorders.
Besides this lack of effect, 25% of the reoperations was
done in this group, most of them with no effect.
Psychological testing or psychiatric evaluation in case of
doubt was advised before implantation of a permanent
system.
A study by Everaert et al. showed similar findings
[25]. In this study, the two-stage procedure was compared
with the single-stage procedure. In the two-stage implant
group, there were no failures during the first stage, while
in the single-stage procedure, three patients had an
immediate failure. They suggested that these results might
be strongly influenced by psychological factors. Mental
disorders were not related to objective or subjective
success but these cofactors surely interfere with symp-
tomatology and therewith co-influencing the results of
therapy.
During the MDT-103 trial (to get the FDA approval) in
89 patients, depression and health-related quality of life
(HRQOL) were assessed [26]. Patients were divided in a
direct implant group and a delayed implant group. At
baseline, they noted detectable levels of depression in 73%
of all patients. After 3 months, patients in the implanted
group had a significant improvement in depression scores.
These improved scores remained at the 6- and 12-month
visits. The scores on the SF-36 questionnaire, a question-
naire to investigate pain, vitality, physical functioning,
social functioning, and mental health, increased in the
implant group for role physical, pain, and social function-
ing. This study demonstrated the serious impact that
unresolved voiding dysfunction has on quality of life.
SNS was associated with significant improvement in
depression and HRQOL.
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Although sacral neuromodulation is planned as a long-term
treatment, the therapy incorporates a unique temporary test
stimulation procedure that allows patients and physicians to
assess sacral nerve stimulation over a trial period [27].
Results of the trial are used by the physician to evaluate the
viability of a permanent surgical implant. This test
stimulation is conducted as an outpatient procedure
preferably under local anesthetic and comprises of two
steps, acute testing and the home evaluation phase. This
testing phase is used to be performed as a PNE test in an
outpatient clinic setting. The original technique was
described by Schmidt et al. and is a simple procedure to
evaluate the effect of sacral neuromodulation [27]. A test
needle is inserted into the third sacral foramen to stimulate
the sacral root. Lead migration is a known complication of
this test, other complications are technical failures or pain
[28]. Some patients who fail a PNE test are still good
candidates for SNS therapy. For these reasons, a two-stage
implant technique was developed [29]. With this technique,
a permanent electrode is implanted and connected to an
external stimulator. Less lead migration and a longer test
period made it possible for clinicians to separate non-
responders from technical failures. Using this two-stage
implant technique, eight out of ten patients who failed a
PNE test had a good result with SNS therapy and were
implanted with a permanent system. A less invasive
technique in combination with a newly designed self-
anchoring lead made it possible to test patients with this
two-stage technique [30, 31]. This “tined lead” has four
sets of self-anchoring tines, which made a minimally
invasive percutaneous placement possible, performed
under local anesthesia, requiring no additional incision
and no additional anchoring. Besides these advantages,
this way of implantation made it possible to test the
sensitive responses during implantation and it resulted in
a reduction of operating time. The “tined lead” staged
implant technique is nowadays widely used in Europe
and the US [32].
The acute phase is used to test the neural integrity and
therefore, sensory and motor responses should be obtained
during this test. The motor responses are important to
identify the right sacral root. Typical S3 stimulation results
in bellows movement of the pelvic floor, plantar flexion of
the great toe, and paraesthesia in the rectum, perineum,
scrotum, or vagina. Stimulation of the other sacral roots
results in different motor responses: S2 gives clamp
movement or twisting and pinching of the anal sphincter
plantar flexion of the entire foot, lateral rotation; S4
stimulation results in bellows motion of the pelvic floor,
no lower extremity activity, and a sensation of pulling in the
rectum [33].
The manual method to localize the S3 foramen is more
difficult for obese patients or those without palpable
landmarks. Alternatively, fluoroscopy can be used for S3
localization. More importantly, the use of lateral imaging
helps to determine the depth required for implanting the S3
lead. The use of fluoroscopic localization of S3 allowed the
introduction of tined S3 lead and transformed the placement
ofaleadfromanopenproceduretoacompletelypercutaneous
one [30, 31]. The widely adopted percutaneous use of a tined
lead approach abandoned the need for fixation of the lead by
methods such as bone anchors.
So nowadays implantation of SNS consists of two steps.
First, a test phase which involves the placement of a
stimulation lead next to the dorsal root of S3 for a test
period between 1–4 weeks. Home evaluation affords the
patient an opportunity to feel the stimulation and enables
the physician to assess the effects of therapy on the voiding
variables. If the patient’s symptoms under the existing list
of indications for SNS improve at least more than 50% then
the patient is a candidate to undergo the stage II or
permanent step in which the permanent implantable pulse
generator (IPG) unit is implanted in the soft tissue of the
buttock of the patient.
During the second stage, the implanted tined lead is
connected to the implantable pulse generator with a
connecting cable that is passed subcutaneously. Relatively
low amplitudes (0–3.0 V) are sufficient for stimulation of
the somatic nerve fibers and to minimize the potential for
nerve damage due to overstimulation. Within the recom-
mended stimulation parameters (210 μS, 10–16 Hz),
continuous stimulation is possible without pain sensation.
Unilateral or bilateral stimulation
Although temporary and chronic SNS can result in
significant permanent clinical improvement, some patients
improve only partially or temporarily [34, 35]. For these
patients, several methods have been developed to improve
the results [30–32]. The most widely accepted method to
test a patient for SNS therapy is unilateral stimulation. In
some clinics, bilateral stimulation has been suggested as a
method to obtain better results [36, 37]. The bilateral
innervation of the bladder is the basis for this type of
intervention [38, 39]. Animal studies were performed to
find a scientific basis for the application of bilateral
neuromodulation. Animal studies by Schultz-Lampel et al.
suggest that bilateral sacral neuromodulation can be a more
effective technique for voiding dysfunction [40]. They
conclude that bilateral stimulation may be more effective at
lower stimulation intensities with positive side effects as
longer stimulator-battery life and less potential nerve
damage.
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compare unilateral approach with bilateral sacral nerve
stimulation is performed by Scheepens et al. [41]. In this
study, 33 patients with chronic voiding dysfunction
underwent unilateral as well as bilateral test stimulation to
assess the possible advantages of bilateral stimulation. All
patients were stimulated during at least 72 h in a unilateral
and a bilateral setting with a washout period of at least 48 h
between these two test periods. Standardized voiding
records were used, and urine was measured using standard
measuring cups. They analyzed results for 12 patients with
urge incontinence and for 13 patients with non-obstructive
urinary retention. They did not find any significant differ-
ences comparing the results for unilateral with bilateral
stimulation. Although two patients of the retention group
started voiding during bilateral stimulation, during unilateral
stimulation they were still in complete retention. The reason
for this remarkable result could be that with bilateral
stimulation sufficient sacral nerve afferents are stimulated to
achieve marked effect at central level.
In conclusion, unilateral stimulation should be performed
before bilateral sacral stimulation is considered. However, a
bilateral test stimulation could be indicated when a unilateral
test fails [41, 42]. Further research with clinical follow-up
could identify suitable patients for bilateral sacral nerve
stimulation.
Clinical results and complications of SNS
In 1999, a prospective randomized study was published
which evaluated the results of SNS therapy for urge
incontinence (UI) were evaluated [43]. In total, 76 patients
were treated in a multicenter trial; 34 patients were
implanted and received chronicle stimulation for 6 months;
after these 6 months, they completed a therapy evaluation
test (on versus off), 42 patients in a delay group were
treated with standard medical therapy for 6 months and
were offered implantation after this period. After 6 months,
the number of daily incontinence episodes, the number of
daily replaced diapers, and the severity of incontinence was
significantly reduced in the stimulation group. In the
stimulation group, 16 patients (47%) were completely dry
and ten patients (29%) showed a greater than 50%
reduction in incontinence episodes. After 18 months, the
efficacy appeared to be sustained. During the therapy
evaluation at 6 months, the stimulation group returned to
baseline symptoms when stimulation was stopped.
Hassouna et al. reported in 2000 on the treatment of
urgency–frequency (UF) symptoms with SNS therapy [44].
In total 51 patients, a stimulation group of 25 patients and a
control group of 26 patients enrolled in this multicenter
trial. All these patients had been tested with a PNE test and
showed satisfactory responses. The stimulation group was
implanted directly after this test, the control group was
implanted after 6 months delay period. Statistically signif-
icant improvements were seen in the stimulation group for
diary parameters as: number of voids daily (16.9±9.7–9.3±
5.1), volume per void (118±74–226±124 ml), and degree
of urgency (rank 2.2±0.6–1.6±0.9). In the control group,
no significant changes were seen. After 6 months, the
stimulation group had an evaluation test and urinary
symptoms returned to baseline when stimulation was turned
off. After reactivation of the stimulation, sustained efficacy
was seen at 12 and 24 months.
A report of use of SNS in urinary retention was
published in 2001 by Jonas et al. One hundred seventy-
seven patients with urinary retention refractory to conser-
vative therapy were enrolled in this multicenter trial
between 1993 and 1998 [45]. Thirty-seven patients were
assigned to treatment and 31 to the control group. At
6 months, the stimulation group showed 69% elimination of
catheterization and an additional 14% with greater than
50% reduction in catheter volume per catheterization.
Temporary inactivation (3 days) of SNS therapy resulted
in significant increase in residual volume. The effectiveness
of SNS therapy was sustained for 18 months after
implantation. The first long-term follow-up results of the
above-mentioned patient series were published in 2000
[28]. Results were reported for 1.5 to 3 years of follow-up.
Of 41 UI patients, 59% showed a greater than 50%
reduction in leaking episodes with 46% of these patients
being completely dry after 3 years. After 2 years offollow-up,
56% of the UF patients showed a greater than 50% reduction
in voids per day. In the retention group, 70% of 42 patients
showed a greater than 50% reduction in catheter volume per
catheterization.
Recently, the 5-year follow-up results of patients included in
the trial, in order to get FDA approval, were analyzed. Of 163
patients enrolled, 152 have been implanted. Of the 152
implanted patients, 96 (63.2%) had UI, 25 (16.4%) UF, and
31 (20.4%) retention. Voiding diaries were collected annually
over 5 years. For UI patients, the mean number of leaking
episodes per day declined from 9.6±6.0 to 3.9±4.0. For UF
patients,meanvoidsperdaydecreasedfrom19.3±7.0to14.8±
7.6. Mean volume voided per void increased from 92.3±52.8
to 165.2±147.7 ml. No life-threatening or irreversible adverse
events occurred. Of 152 patients, 102 experienced 33 device-
related and 246 therapy-related adverse events. At 5 years,
68.0% of UI, 56.0% of UF, and 71.0% of retention patients had
successful outcomes. However, an important finding in this
study is the high correlation between the 1- and 5-year success
rates. Of the implanted patients, 84% with UI, 71% with UF,
and 78% withretentioncontinuedtohave a successfuloutcome
at 5-year follow-up if successful at 1 year [46]. Different clinics
have published their long-term results in the previous years
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effective therapy.
All the above-mentioned studies reported on complications
during SNS. Siegel et al. summarized the complications in
patientswithrefractoryurgeincontinence,urgency–frequency,
and urinaryretentionthatwere includedintheoriginal trials of
SNS [28]. The complications were divided in PNE-related
complications and implant-related problems. Of the 914 test
stimulation procedures done on the 581 patients, 181 adverse
events occurred in 166 of these procedures (18.2% of the 914
procedures). The vast majority of complications were related
to lead migration (108 events, 11.8% of procedures).
Technical problems and pain represented 2.6% and 2.1% of
the adverse events. For the 219 patient who underwent
implantation of the permanent system, the following adverse
events were seen during follow-up: pain at neurostimulator
site (15.3%), new pain (9%), suspected lead migration
(8.4%), transient electric shock (5.5%), pain at lead site
(5.4%), adverse change in bowel function (3.0%), and some
less frequent events like technical problems, device problems,
change in menstrual cycle, and others. Surgical revisions of
the implanted neurostimulator or lead system were performed
in 33.3% of cases (73 of 219 patients) to resolve an adverse
event. Mostly, this was done to relocate the stimulator
because of pain or because of suspected lead migration. No
serious adverse events, side effects, or permanent injury was
reported.
Recently our long-term follow-up results with compli-
cation rates were published [47]. Of 149 patients analyzed,
107 had overactive bladder symptoms and 42 had urinary
retention. Mean follow-up was 64.2 (SD=38.5)months. In
the whole group, 194 adverse events occurred. Six patients
had infection in their implanted system, one was explanted
for infection. Most events could be solved by giving advice
or by reprogramming the stimulator. One hundred twenty-
nine reoperations have been performed and 21 patients had
their system explanted. Analysis of the data shows a
striking difference in the incidence of reoperations, but
small differences in subjective results in the groups of
patients implanted before or after 1996, suggesting that a
proactive approach towards adverse events is worthwhile.
In our experience with the tined lead implantation, we see a
clear decrease in reoperation rate [50]. Of 39 patients
implanted with the tined lead, Voskuilen et al. described
seven severe adverse events on medium term, three of these
needed a reoperation. Three patients could be treated with
one or two reprogramming sessions. Three patients had a
reoperation to reposition the IPG after complaints of pain.
These three patients had good results afterwards. One
patient with an incomplete spinal cord lesion has no benefit
of the implanted system.
Of 161 patients implanted with the tined lead between
July 2002 and September 2004, Hijaz et al. described the
complications seen in their institute [51]. They had three
categories for complications: infections, mechanical prob-
lems, and response-related dysfunction. In total, they
reported 17 explantations(10.5%). Eight explantations were
done due to infection and seven due to loss of effect. In 26
(16.1%) patients, they performed a revision after these
patients presented with a decrease in clinical response. The
reasons for revision were: mechanical (lead) problems, IPG
site discomfort, lead migration, and infectious causes.
These complication rates show a decrease over the years
mainly due to technical and procedural improvements.
Gaynor-Krupnick et al. as well as Hijaz and Vasada
presented an algorithm for evaluation and managing of a
malfunctioning neuromodulation system [52, 53].
Expanding indications
With the widespread use, incidental improvements were
published for other pathological conditions. Use of SNS for
other off-label applications has been reported for treatment
of interstitial cystitis, chronic pelvic pain, pediatric voiding
dysfunction, and neurogenic lower urinary dysfunction seen
in multiple sclerosis.
In 2000, the first papers were published with positive
results with the use of SNS in interstitial cystitis [54, 55].
Comiter evaluated the effect of SNS therapy for interstitial
cystitis in a prospective study in 2003 [56]. Seventeen out
of 25 patients were implanted with a permanent system.
After a mean follow-up of 14 months, there were significant
improvements in daytime frequency and nocturia improved
from 17.1 to 8.7 and 4.5 to 1.1, respectively (p<0.01). Mean
voided volume increased from 111 to 264 ml (p<0.01).
Average pain score decreased from 5.8 to 1.6 points on a
scale of 0 to 10 (p<0.01). Interstitial cystitis symptom and
problem index scores decreased from 16.5 to 6.8 and 14.5 to
5.4, respectively (p<0.01).
Chronic pelvic pain or genitourinary pain is a hard to treat
condition. Over the years, some cases were presented of
patients implanted with a SNS system for these conditions. In
2001, Siegel et al. implanted ten patients with a permanent
system[57]. After 9 months of follow-up, nine of ten patients
had a decrease in most severe pain scores; after a median
follow-up of 19 months, six out of ten patients reported
significant improvement in pain symptomatology.
After the clinical implication of SNS therapy for voiding
dysfunction, Matzel together with Schmidt and Tanagho
started to investigate SNS therapy in bowel dysfunction
[58, 59]. In a prospective non-randomized multicentre
study, 37 patients underwent test stimulation with SNS
therapy for fecal incontinence [60]. Thirty-four patients
were implanted with a permanent system. The effect on
incontinence was assessed by daily bowel habit diaries and
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quency of incontinent episodes per week decreased from
16.4 to 3.1 at 12 months and to 2.0 at 24 months for both
urge and passive incontinence. The mean number of
incontinence episodes per week, staining, and pad use
declined significantly too. Quality of life improved signif-
icantly in ASCRS scales; in the SF-36 scales only social
functioning improved significantly.
Jarrett et al. did a systematic review of SNS for fecal
incontinence and constipation [61]. They reported total
continence in 41–75% of the patients, 75–100% experi-
enced improvement in the incontinence symptoms. The
results for patients treated with SNS for constipation
discussed in this review seem promising but limited data
is available by this time.
The results of SNS therapy in children with neurogenic
bladder dysfunction is described by Guys et al. [62]. In total,
42 children with neurogenic bladder dysfunction, mainly due
to spina bifida, enrolled in this prospective randomized
controlled trial. Twenty-one patients were treated conserva-
tively, while the other 21 patients were treated with SNS
therapy. After 12 months, no significant better results were
seen in the group treated with SNS. The authors stated that
probably the intervention group was too small or the bladder
dysfunction in these patients too severe.
Sexuality
During routine follow-up, patients may report improved
sexual functioning after implant. Pauls et al. recently
reported a pilot study to determine if sacral neuromodula-
tion has an effect on the patient’s subsequent sexual
function [63]. Eleven patients with a permanent system
implanted were questioned about their sexual function
before and after implantation. With SNS therapy, sexual
frequency and female sexual function index (FSFI)
increased significantly. No correlation was found between
improvement in urinary symptoms and FSFI scores.
Conclusions
After years of experimental therapy, initiated by Tanagho
and Schmidt, sacral nerve stimulation is nowadays a widely
used therapy. Although the mechanism for this therapy is
still not fully understood, the therapy has been proven
effective on the long term. Due to the less invasive
technique and other technical improvements, it is expected
that complication rates will further decrease within the
coming years. The expanding use of SNS therapy in fields
other than urology will probably result in FDA approval for
gastrointestinal indications.
Further research, possible with the help of animal models,
has to be performed to understand in a more precise way the
mechanism of SNS therapy. Other goals in research could be:
patient selection (finding ways to identify more appropriate
candidates), the effect of sacral neuromodulation in combined
(urology–gynecology–GI) pathology, the effect of bilateral
versus unilateral stimulation.
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